May 21, 2021 - Evolution of FMT

Evolution of FMT – From Early Clinical to Standardized Treatments
A Virtual Meeting
15:00 - 18:00 CEST // 9:00am - 12:00pm EDT

Agenda

Slides

Meeting objectives

Faecal microbiota transplantation (FMT) is widely reported to be an effective treatment against recurrent Clostridium difficile infections. Recent clinical evidences support the therapeutic use of FMT for several other pathologies including inflammatory bowel disease, cancer and other functional or metabolic disorders.

Initial guidelines are now available to overcome some of the technical and logistical issues in establishing a non-standardised treatment into clinical practice with proper safety and governance.

 

Along with recent clinical successes of FMT, the webinar aims to provide a multi-disciplinary perspective of ongoing efforts to develop FMT guidelines including technical, regulatory, and standardization requirements.

Recognized experts will give insights into state-of-the art approaches and standards developed by international organizations and institutions.

 

Speakers:

Dr. Hervé Affagard, MaaT Pharma
Biosketch
Abstract

Dr. Chrysi Sergaki, NIBSC
Biosketch Abstract

Prof. Harry Sokol, St. Antoine Hospital, Paris
Biosketch Abstract

Dr. Vincent Thomas, Bioaster
Biosketch Abstract

Panelists
Dr. Jennifer Wargo, MD Anderson Cancer Center
Biosketch

Dr. Gary Wu, University of Pennsylvania
Biosketch

 

Scientific Committee
Phil Daschner, NIH
Cyril Guyard, Bioaster
Shawn Novick, IABS
Philippe Sabot, IABS
Stephanie Servetas, NIST
Vincent Thomas, Bioaster

With our Thanks to our Sponsors,

 

View the webinar:

 

International Alliance for Biological Standardization


Twitter Feed

@NCICancerBio Thanks to Dr Phil Daschner ! more info : https://t.co/VNvQGQ2Gx1
#IABSnews We are proud to welcome Norman W. Baylor in the position of Editor-in-Chief of IABS' Journal BIOLOGICALS… https://t.co/agXaGj099U
Follow IABS_global on Twitter

Contact Info

IABS, Rue Mina-Audemars, 3
CH-1204 Geneva

Switzerland
+ 41 22 301 10 36
This email address is being protected from spambots. You need JavaScript enabled to view it.